Skip to main content
. 2015 Jun 22;80(4):630–641. doi: 10.1111/bcp.12649

Figure 4.

Figure 4

Effect of covariates on typical PK profiles of tacrolimus: A) formulation type, B) CYP3A5 genotype assuming the administration of Prograf® and C) total dose of tacrolimus (DTOT) assuming the administration of Prograf® (dose normalized blood concentration profiles) Inline graphic Prograf®, Inline graphic Limustin®, Inline graphic Framebin®, Inline graphic Tenacrine®, Inline graphic *1/*1, Inline graphic *1/*3, Inline graphic*3/*3, Inline graphic 0.5 mg, Inline graphic 1 mg, Inline graphic 1.5 mg, Inline graphic 2 mg, Inline graphic 2.5 mg